Description
Paxobrook (Nirmatrelvir 150 mg + Ritonavir 100 mg)
Paxobrook is a generic version of the antiviral drug Paxlovid, formulated to treat mild to moderate COVID-19 in individuals at high risk of progressing to severe disease. It combines two antiviral agents:
- Nirmatrelvir 150 mg – inhibits SARS-CoV-2 viral replication.
- Ritonavir 100 mg – boosts the effectiveness of nirmatrelvir by slowing its breakdown.
Paxobrook is most effective when started within 5 days of COVID-19 symptom onset.
Key Benefits
- Reduces risk of hospitalization and severe illness from COVID-19
- Oral tablets – no injection required
- Generic, cost-effective alternative to Paxlovid
- Suitable for adults and children (12+ years, ≥40 kg)
Product Details
- Brand: Paxobrook
- Generic Name: Nirmatrelvir + Ritonavir
- Form: Oral tablets
- Packaging: 30 tablets per box (5-day course)
Dosage & Administration
- Take 2 tablets of Nirmatrelvir 150 mg and 1 tablet of Ritonavir 100 mg together.
- Repeat this dose twice daily for 5 consecutive days.
- Do not crush or chew the tablets.
- Start treatment as early as possible, ideally within 5 days of symptom onset.
Precautions
- Not suitable for patients with severe kidney or liver impairment.
- Consult a doctor if pregnant, breastfeeding, or taking other medications.
- Ritonavir can interact with many other drugs – disclose your medication history to your doctor.
Possible Side Effects
- Metallic or altered taste
- Diarrhea
- Muscle aches
- High blood pressure
- Rare: Allergic reactions or liver enzyme changes
FAQs
Q1: What is Paxobrook used for?
Paxobrook is used to treat mild to moderate COVID-19 in patients at high risk of developing severe symptoms.
Q2: Is Paxobrook the same as Paxlovid?
Yes, it contains the same active ingredients – Nirmatrelvir and Ritonavir – and offers similar antiviral effects at a more affordable price.
Q3: Can I take Paxobrook without symptoms?
No. Paxobrook is not for prevention. It is only effective when taken shortly after COVID-19 symptoms appear.
Q4: Can children take Paxobrook?
It is approved for children 12 years and older who weigh at least 40 kg (88 lbs), under medical supervision.
